Research Topics
Genomes and Genes | Fenghuang ZhanSummaryAffiliation: University of Arkansas for Medical Sciences Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasiaEun Sung Park
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
BMC Genomics 8:302. 2007....- CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanismsFenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
Blood 109:4995-5001. 2007.... - Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 115:61-70. 2010..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib... - The molecular classification of multiple myelomaFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 108:2020-8. 2006..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature... - RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myelomaSiqing Wang
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
Blood 114:600-7. 2009..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM... 
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survivalYun Ge
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 133:83-92. 2006..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsSimona Colla
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 109:4470-7. 2007..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression... - A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2276-84. 2007..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions... - Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatioIchiro Hanamura
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, USA
Blood 108:1724-32. 2006..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis... - Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoShmuel Yaccoby
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2106-11. 2007..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth... - The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myelomaErming Tian
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, College of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205, USA
N Engl J Med 349:2483-94. 2003..Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both... - Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
Mol Cancer Ther 8:2616-24. 2009.... - Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 109:1692-700. 2007..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias... - Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin
Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Virology 331:269-91. 2005.... - Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003.... - An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaWei Xiong
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:4235-46. 2008..These data suggest that loss of TP53 expression in MM confers high risk and probably results in the deregulation of a novel set of MM-specific TP53-target genes. TP53 target gene specificity may be unique to different cell lineages... - The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotypeClive S Zent
Division of Hematology Oncology, Central Arkansas Healthcare System and University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
Leuk Res 27:765-74. 2003..CLL and MM differentially expressed 18% of 130 apoptosis related genes, suggesting differences in mechanisms of cell survival... - Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell linesXin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:802-11. 2007..These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy... - Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell developmentFenghuang Zhan
Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 101:1128-40. 2003..000 09). MM1 showed no significant linkage with normal cell types studied. Thus, genes whose expression is linked to distinct transitions in late-stage B-cell differentiation can be used to classify MM... - Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Immunother 30:847-54. 2007..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM... - Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profilingFenghuang Zhan
Donna D and m Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 40:308-20. 2003..Here we discuss recent progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of PCs from healthy individuals and patients with MM and other PC dyscrasias... - Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Blood 99:1745-57. 2002..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM... 
Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphomaAmy Heerema-McKenney
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, USA
Am J Clin Pathol 133:265-70. 2010..Most cases share a common GEP signature dominated by hyperexpression of cyclin D1 or cyclin D3 genes, with increased expression of the B-cell genes CD20 and VPREB3...- High heparanase activity in multiple myeloma is associated with elevated microvessel densityThomas Kelly
Departments of Pathology, Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
Cancer Res 63:8749-56. 2003.... - A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcriptMadhumita Santra
Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:2374-6. 2003..These data indicate that the t(4;14)(p16;q32) and loss of FGFR3 occurred at a very early stage and suggest that activation of MMSET, not FGFR3, may be the critical transforming event of this recurrent translocation... - Gene expression profiling and multiple myelomaJohn Shaughnessy
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, AR, USA
Best Pract Res Clin Haematol 18:537-52. 2005..Expression profiling has also led to the identification of a number of new therapeutic targets not only in myeloma cell survival but also in the pathogenesis of the osteolysis which is a hallmark of this disease... - NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
Blood 105:3939-44. 2005..The pool of NY-ESO-1-specific cytotoxic T cells expands easily on NY-ESO-1 peptide stimulation and is functionally active. NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM... - Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapyAlessandro D Santin
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
Int J Cancer 112:14-25. 2004..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease... - CGO: utilizing and integrating gene expression microarray data in clinical research and data managementKlaus Bumm
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics and Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bioinformatics 18:327-8. 2002.... - Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 13:7073-9. 2007..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma... - CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk diseaseJeroen E J Guikema
Department of Cell Biology, Histology and Immunology Section, University Hospital, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
Br J Haematol 121:36-43. 2003..In conclusion, CD27 is heterogeneously expressed on MM PC and loss of CD27 expression might have prognostic value in MM... - CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi
Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Cancer Res 14:2775-84. 2008.... - Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myelomaBart Burington
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 14:4821-9. 2008..Genes whose drug-altered expression were found to be related to survival may point to molecular switches related to response and/or resistance to different classes of drugs... - Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiationKarin Tarte
INSERM U475, 99, Montpellier, France
Blood 102:592-600. 2003..These data should help to better understand the molecular events that regulate commitment to a PC fate, mediate PC maintenance in survival niches, and could facilitate PC immortalization in plasma cell dyscrasias... - Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablastsKarin Tarte
, CHU Montpellier, France
Blood 100:1113-22. 2002..In addition, the comparison of gene expression between plasmablastic cells and B cells provides a new and powerful tool to identify genes specifically involved in normal plasma cell differentiation... - High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Cell 9:313-25. 2006.... - RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell
Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
Blood 104:1151-8. 2004..The RHAMM-exon4/RHAMMFL ratio in diagnostic bone marrow samples (n=101, Alberta) is an independent prognostic factor. Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM... - Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cellsUnn Merete Fagerli
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
Blood 111:806-15. 2008..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells... - ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myelomaAtsushi Suzuki
Cancer Physiology Project, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Oncogene 24:6936-44. 2005..Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas... - Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaP Leif Bergsagel
Mayo Clinic Scottsdale, Comprehensive Cancer Center and Division of Hematology Oncology, Scottsdale, AZ, USA
Blood 106:296-303. 2005..However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor... - Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibGeorge Mulligan
Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
Blood 109:3177-88. 2007..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents... - Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasisYang Yang
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
J Biol Chem 282:13326-33. 2007..These results reveal a new mechanism by which heparanase promotes an aggressive tumor phenotype and suggests that heparanase and syndecan-1 act synergistically to fine tune the tumor microenvironment and ensure robust tumor growth... - Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:1587-94. 2007..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM... - Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Cell 12:115-30. 2007..These data demonstrate that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease... - High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasoneFenghuang Zhan
Blood 111:968-9. 2008 - Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarrayPei Lin
Department of Pathology, University of Arkansas for Medical Science, USA
Mod Pathol 17:1217-22. 2004..We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation... - Smoldering multiple myelomaH Keshava Prasad
N Engl J Med 357:1048; author reply 1049-50. 2007